Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Neurogen

Executive Summary

Harry Penner to president, CEO and a board member of the Branford, Conn. CNS biopharmaceutical R&D firm. Penner, 48, succeeds Philip Whitcome, who is stepping down for personal reasons, Neurogen says Oct. 28. Penner joins the company Dec. 1. Penner, who was at Novo Nordisk 12 years, most recently held the position of company president in the U.S. and a member of the corporate management team. On an interim basis, the New York corporate office will report to Chief Financial Officer Kurt Anker Neilsen.
Advertisement
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS023523

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel